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Association Between Alcohol Use Disorders andOutcomes
of Patients HospitalizedWith Community-Acquired Pneumonia
Niyati M. Gupta, MD; Peter K. Lindenauer, MD, MSc; Pei-Chun Yu, MS; Peter B. Imrey, PhD; Sarah Haessler, MD; Abhishek Deshpande, MD, PhD;
Thomas L. Higgins, MD, MBA; Michael B. Rothberg, MD, MPH
Abstract
IMPORTANCE Patients with alcohol use disorder (AUD) are at elevated risk of developing
pneumonia, but few studies have assessed the outcomes of pneumonia in patients with AUD.
OBJECTIVES To compare the causes, treatment, and outcomes of pneumonia in patients with and
without AUD and to understand the associations of comorbid illnesses, alcohol withdrawal, and any
residual effects due to alcohol itself with patient outcomes.
DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study was conducted of 137 496
patients 18 years or older with pneumonia whowere admitted to 177 US hospitals participating in the
Premier Healthcare Database from July 1, 2010, to June 30, 2015. Statistical analysis was conducted
fromOctober 27, 2017, to August 20, 2018.
EXPOSURE Alcohol use disorders identified from International Classification of Diseases, Ninth
Revision, Clinical Modification codes.
MAINOUTCOMESANDMEASURES Pneumonia cause, antibiotic treatment, inpatient mortality,
clinical deterioration, length of stay, and cost. Associations of AUDwith these variables were studied
using generalized linear mixedmodels.
RESULTS Of 137 496 patients with community-acquired pneumonia (70 358women and 67 138
men; mean [SD] age, 69.5 [16.2] years), 3.5% had an AUD. Patients with an AUDwere younger than
those without an AUD (median age, 58.0 vs 73.0 years; P < .001), more often male (77.3% vs 47.8%;
P < .001), andmore often had principal diagnoses of aspiration pneumonia (10.9% vs 9.8%;
P < .001), sepsis (38.6% vs 30.7%; P < .001), or respiratory failure (9.3% vs 5.5%; P < .001). Their
cultures more often grew Streptococcus pneumoniae (43.7% vs 25.5%; P < .001) and less frequently
grew organisms resistant to guideline-recommended antibiotics (25.0% vs 43.7%; P < .001).
Patients with an AUDwere treatedmore often with piperacillin-tazobactam (26.2% vs 22.5%;
P < .001) but equally as often with anti–methicillin-resistant Staphylococcus aureus agents (32.9% vs
31.8%; P = .11) compared with patients without AUDs. When adjusted for demographic
characteristics and insurance, AUDwas associated with higher mortality (odds ratio, 1.40; 95% CI,
1.25-1.56), length of stay (risk-adjusted geometric mean ratio, 1.24; 95% CI, 1.20-1.27), and costs (risk-
adjusted geometric mean ratio, 1.33; 95% CI, 1.28-1.38). After additional adjustment for differences
in comorbidities and risk factors for resistant organisms, AUDwas no longer associatedwithmortality
but remained associated with late mechanical ventilation (odds ratio, 1.28; 95% CI, 1.12-1.46), length
of stay (risk-adjusted geometric mean ratio, 1.04; 95% CI, 1.01-1.06), and costs (risk-adjusted
geometric mean ratio, 1.06; 95% CI, 1.03-1.09). Models segregating patients undergoing alcohol
(continued)
Key Points
Question What is the etiology of
pneumonia among patients with alcohol
use disorder, and is alcohol use disorder
associated with poorer outcomes?
Findings In this cohort study of 137 496
patients with pneumonia, the most
common cause of pneumonia among
patients with alcohol use disorder was
Streptococcus pneumoniae; resistant
gram-negative infections were rare. In
comorbidity-adjusted models, alcohol
use disorder was not significantly
associated with inpatient mortality, but
patients with alcohol use disorder
undergoing alcohol withdrawal more
frequently required late mechanical
ventilation, vasopressors, and intensive
care unit admissions and had increased
lengths of stay and hospital costs.
Meaning This study suggests that
alcohol use disorder alone is not an
independent risk factor for resistant
infection or mortality, but alcohol
withdrawal is associated with clinical
deterioration and higher use of health
care resources.
+ Invited Commentary
+ Supplemental content
Author affiliations and article information are
listed at the end of this article.
Open Access. This is an open access article distributed under the terms of the CC-BY License.
JAMA Network Open. 2019;2(6):e195172. doi:10.1001/jamanetworkopen.2019.5172 (Reprinted) June 7, 2019 1/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 07/29/2019
Abstract (continued)
withdrawal showed that poorer outcomes among patients with AUDwere confined to the subgroup
undergoing alcohol withdrawal.
CONCLUSIONS ANDRELEVANCE This study suggests that, compared with hospitalized patients
with community-acquired pneumonia but without AUD, those with AUD less often harbor resistant
organisms. The higher age-adjusted risk of death among patients with AUD appears to be largely
attributable to differences in comorbidities, whereas greater use of health care resources may be
attributable to alcohol withdrawal.
JAMA Network Open. 2019;2(6):e195172. doi:10.1001/jamanetworkopen.2019.5172
Introduction
Community-acquired pneumonia (CAP) is the sixth leading cause of death in the United States and
the most common cause of infectious disease mortality.1 Underlying conditions including age,
immune status, smoking, and comorbidities influence the severity of CAP.2 Alcohol use disorder
(AUD) affects 15.1 million US adults3 and approximately 4%of patients hospitalizedwith pneumonia.4
Compared with patients without AUD, those with AUD tend to havemore severe clinical
presentations2 and greater use of health care resources, including intensive care.2,4
There are several potential explanations for these poorer outcomes. First, alcohol can affect
oropharyngeal flora, promoting colonization with resistant gram-negative organisms.5-7 Alcohol
consumption also blunts the cough and gag reflexes, predisposing patients to aspirate these
organisms.8 Second, alcohol adversely affects immune function and pulmonary clearing
mechanisms, impairing the body’s ability to fight infection.9,10 Malnutrition, which is common among
patients with AUD,may amplify these effects.11 Third, long-term alcohol use damages organ systems,
leading to liver disease, cardiovascular disorders, kidney disease, and cancer.12 Fourth, AUD puts
patients at risk for alcohol withdrawal syndrome (AWS), which is itself a cause of increased use of
health care resources andmortality.13
Despite the prevalence of AUD, few large studies have evaluated the effects of AUD in
pneumonia. None has sought to attribute the poorer outcomes of patients with AUD to these various
potential causes. The objective of this studywas to better informmanagement of patients with AUD
by identifying the bacterial causes of pneumonia in a large sample of US hospitals, describing
antibiotic resistance and treatment patterns, and assessing AUD’s association with outcomes of
pneumonia, including the specific contributions of comorbidities, AWS, and any residual differences
that are potentially attributable to alcohol’s direct immunosuppressive effects. These questions have
important implications for clinical care (eg, choosing initial antibiotic therapy and admission to
intensive care) as well as risk adjustment.
Methods
Study Population
We conducted a retrospective cohort study of patients 18 years or older whowere admitted between
July 1, 2010, and June 30, 2015, to 177 US hospitals participating in the Premier Healthcare Database
(Premier Inc),14 an inpatient database developed for measuring quality and use of health care
resources. Data were provided by participating hospitals from all regions of the United States and are
in most respects representative of US acute care hospitals, although larger hospitals, the southern
region, and urban facilities are overrepresented. The Premier Database contains sociodemographic
information; hospital and physician information; International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnosis codes; and date-stamped hospital charge codes
for all items charged to the patient or insurer, including medications, laboratory or diagnostic tests,
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and procedures. Approximately three-quarters of the participating hospitals provide information on
actual hospital costs, and the remainder provide cost estimates based on Medicare cost to charge
ratios. Themicrobiology laboratory data, including culture results and antibiotic sensitivity results,
were available for hospitals that used SafetySurveillor (Premier Inc), an infection tracking tool.
Because the Premier Healthcare Database includes only affirmative charges, missing data on
chargeable events are not readily detectable. Missing demographic fields were very rare, and the few
such patients with themwere omitted. Because all data from the database are deidentified and
contain no protected health information, the study protocol was deemed exempt by the institutional
review board of The Cleveland Clinic Foundation. This study followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Patients with a primary diagnosis of pneumonia (ICD-9-CM codes: 481, 482.0-482.9, 483.0-
483.8, 484.0-484.8, 485, 486, and 507.0) or a primary diagnosis of respiratory failure (ICD-9-CM
codes: 518.81, 518.82, 518.84, and 799.1) or sepsis (ICD-9-CM codes: 785.52, 790.7, 995.91, 995.92,
and 038.0-038.9) combined with a secondary diagnosis of pneumonia were included in the study
(eTable 1 in the Supplement). To increase the specificity of the diagnosis, we also required patients to
undergo chest radiography, to have received antibiotics, and to have had blood or respiratory
cultures collected by the first hospital day.
Patients with cystic fibrosis, those with potential causes of bacteremia other than pneumonia
(cholecystitis, appendicitis, diverticulitis, perforated diverticulum, peritonitis, postoperative
anastomotic leaks or abdominal surgical site infections, central line–associated bloodstream infection
with positive blood culture results, or endocarditis with Staphylococcus aureus or viridans group
Streptococci in blood), and patients receiving long-termmechanical ventilation or who were
transferred from another acute care facility were excluded because wewere not interested in
studying the bacteriology of pneumonia facilitated by these other conditions. Patients with the same
organism in blood and urine cultures (representing urinary pathogens), enterococcal infection (which
is not a cause of pneumonia), positive Streptococcus or Legionella pneumonia antigen test results in
the current admission and within the past 6months (because antigen positivity may persist for up to
6months), or the same pneumonia diagnosis in the current admission and a previous admission
within 1 year (because previous diagnosesmay be carried forward) were also excluded (eFigure in the
Supplement).
Baseline Variables
We used ICD-9-CM codes (eTable 2 in the Supplement) to identify AUD (codes 291.0, 291.81-291.89,
291.9, 303.0-303.92, and 305.00-305.02) and AWS (codes 291.81 and 291.0). Patients who had
ICD-9-CM codes indicating AUD in remission (codes 303.03, 303.93 and 305.03) were excluded from
the study; although they had a high burden of comorbidity, they were presumably not at elevated
risk for colonization by resistant gram-negative bacteria, aspiration, immunosuppression due to
alcohol, or alcohol withdrawal.
Additional variables included demographic characteristics (age, sex, race, and health insurance
status), comorbidities (identified using secondary ICD-9-CM codes and diagnosis related group based
on the work of Elixhauser15), risk factors for resistant infections (admission from a skilled nursing
facility or intermediate care facility, prior admission within 6months, dialysis, and immune status),16
hospital characteristics (geographical region, urban vs rural location, bed size, and teaching status),
and certain treatments on hospital day 1 (admission to an intensive care unit [ICU], administration of
vasopressors, invasive mechanical ventilation [IMV], and type and number of antibiotics
administered).
Microbiological Evaluation
We considered all blood and respiratory samples collected by hospital day 1. Positive cultures were
used to identify the cause of pneumonia as well as to study antibiotic resistance patterns reported by
the hospital laboratories. Organismswere considered resistant to CAP therapy if they demonstrated
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intermediate or greater resistance to treatment with either a quinolone or a third-generation
cephalosporin plus a macrolide.
Outcomes
Outcomes included inpatient mortality, clinical deterioration (as evidenced by late ICU transfer, late
IMV, or late vasopressor therapy initiation [ie, after the first hospital day]), length of stay (LOS), and
cost. Hospital costs represented the entire cost of hospitalization, including bed charge, laboratory
tests, andmedications.
Statistical Analysis
Statistical analysis was conducted fromOctober 27, 2017, to August 20, 2018. We summarized and
compared baseline characteristics between patients with and without AUD by using frequencies,
proportions, and Pearson χ2 tests for categorical variables andmedians, quartiles, and Kruskal-Wallis
rank analysis of variance tests for continuous variables.We described the frequencies of pneumonia
causes in 2 ways: as the fractions of patients from whom the organism was cultured in any blood or
respiratory sample both in the subset of patients with any positive culture of either type and among
all cultured patients.
We usedmixed logistic regression with random hospital effects to model the dichotomous
outcomes of death and signs of clinical deterioration. To understand the relative contributions of
comorbidities, AWS, and any residual effects that might be attributed to the direct
immunosuppressive effects of alcohol,4 we performed stagewise adjusted analyses. First, we
adjusted only for patient demographic characteristics (Table 1). Second, we added to themodel the
comorbidities and risk factors for resistant infections in Table 1. Third, we stratified results by the
presence or absence of AWS.We thenmeasured the remaining effect of AUD, whichmight be due to
the direct immunosuppressive effects of alcohol. Models were prespecified without data-driven
variable selection. Analogous sequences of gamma generalized linear mixedmodels17,18 with log link
function were used for LOS and cost. All our models included random hospital intercept effects. In
unadjusted and final adjusted analyses, we first expressed AUD as a dichotomous effect and then as
a trichotomy, further distinguishing between AUDwith andwithout AWS. Models were fitted using
residual subject-specific pseudolikelihood, and Wald statistics and 95% CIs were used for formal
inference. In final models, inferences for overall AUD effects were based on sample-size weighted
linear combinations of estimated parameters for the subgroups undergoing and not undergoing
alcohol withdrawal. Results of logistic models are summarized as odds ratios (ORs) and of gamma
models as ratios of geometric means, each with 95% CIs. Analyses were performed using SAS,
version 9.4 (SAS Institute Inc). All P values were from 2-sided tests, and results were deemed
statistically significant at P < .05.
Results
Patient characteristics appear in Table 1. Of 137 496 patients hospitalized with pneumonia, the mean
(SD) age was 69.5 (16.2) years and 3.5% had an AUD. Compared with patients without AUD, those
with AUD were younger (median age, 58.0 vs 73.0 years; P < .001), more often male (77.3% vs
47.8%; P < .001), black (17.1% vs 12.3%; P < .001), and insured byMedicaid (21.8% vs 8.1%; P < .001).
Patients with AUD hadmore comorbid conditions. In particular, they were more likely to smoke
(61.1% vs 16.7%; P < .001), have chronic liver disease (20.4% vs 2.5%; P < .001), have weight loss
(20.5% vs 12.5%; P < .001), have psychoses (11.0% vs 6.1%; P < .001), and to abuse drugs other than
alcohol (17.8% vs 2.7%; P < .001). Patients with AUD also presented with more severe illness: they
were more likely to have a principal diagnosis of aspiration pneumonia (10.9% vs 9.8%; P < .001),
sepsis (38.6% vs 30.7%; P < .001), or respiratory failure (9.3% vs 5.5%; P < .001) (Table 1); to be
admitted to the ICU (39.0% vs 24.3%; P < .001) (Table 2); and to receive vasopressors (11.3% vs
6.2%; P < .001) or IMV (16.4% vs 7.5%; P < .001). Patients with AUDweremore likely to have been
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Table 1. Baseline Patient Characteristics
Characteristic
No. (%)a
No AUD (n = 132 744) AUD (n = 4752)
Principal diagnosis
Pneumonia 71 805 (54.1) 1958 (41.2)
Aspiration pneumonia 12 946 (9.8) 519 (10.9)
Sepsis 40 740 (30.7) 1832 (38.6)
Respiratory failure 7253 (5.5) 443 (9.3)
Demographics
Age, median (IQR), y 73.0 (60.0-83.0) 58.0 (50.0-67.0)
Age group, y
18-44 10 774 (8.1) 633 (13.3)
45-64 32 933 (24.8) 2669 (56.2)
65-74 27 070 (20.4) 901 (19.0)
75-84 32 469 (24.5) 417 (8.8)
≥85 29 498 (22.2) 132 (2.8)
Sex
Male 63 466 (47.8) 3672 (77.3)
Female 69 278 (52.2) 1080 (22.7)
Race
White 102 672 (77.3) 3501 (73.7)
Black 16 351 (12.3) 814 (17.1)
Hispanic 870 (0.7) 31 (0.7)
Other 12 851 (9.7) 406 (8.5)
Insurance payer
Medicare 96 761 (72.9) 1973 (41.5)
Medicaid 10 751 (8.1) 1036 (21.8)
Managed care 14 150 (10.7) 670 (14.1)
Commercial indemnity 4090 (3.1) 209 (4.4)
Others 6992 (5.3) 864 (18.2)
HCAP components
Admitted from SNF or ICF 10 181 (7.7) 138 (2.9)
Dialysis 6045 (4.6) 106 (2.2)
Admission within past 6 mo 13 011 (9.8) 313 (6.6)
Immunosuppressed 20 644 (15.6) 673 (14.2)
Comorbidities
Hypertension 88 151 (66.4) 2622 (55.2)
Fluid and electrolyte disorders 65 035 (49.0) 3019 (63.5)
Chronic pulmonary disease 61 501 (46.3) 2484 (52.3)
Diabetes 43 882 (33.1) 898 (18.9)
Deficiency anemias 43 005 (32.4) 1481 (31.2)
Congestive heart failure 37 303 (28.1) 935 (19.7)
Smoker 22 146 (16.7) 2905 (61.1)
Chronic kidney disease 24 158 (18.2) 427 (9.0)
Hypothyroidism 23 046 (17.4) 347 (7.3)
Other neurologic disorders 22 517 (17.0) 694 (14.6)
Depression 20 683 (15.6) 785 (16.5)
Obesity 17 930 (13.5) 455 (9.6)
Weight loss 16 617 (12.5) 974 (20.5)
Valvular disease 12 799 (9.6) 297 (6.3)
Coagulopathy 11 650 (8.8) 892 (18.8)
Peripheral vascular disease 10 982 (8.3) 287 (6.0)
Pulmonary circulation disease 10 483 (7.9) 310 (6.5)
(continued)
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admitted to larger hospitals (401 beds) (42.6% vs 35.7%; P < .001) and teaching hospitals (45.7%
vs 40.5%; P < .001), with little variation by geography or urban location (eTable 3 in the Supplement).
Cause of Pneumonia andAntibiotic Treatment
A higher percentage of patients with AUD than patients without AUD yielded positive cultures (13.4%
vs 9.1%; P < .001). Among those with positive cultures, patients with AUDmore often had
Streptococcus pneumoniae (43.7% vs 25.5%; P < .001) and less often Klebsiella pneumoniae (6.0%
vs 7.3%; P = .02), Pseudomonas aeruginosa (4.6% vs 12.9%; P < .001), and any organisms resistant to
guideline-recommended therapy for CAP (25.0%vs 43.7%; P < .001) than did patients without AUD
(Figure 1). Among all patients (including those with negative cultures), the corresponding
percentages for those with andwithout AUDwere 5.9% vs 2.3% for S pneumoniae, 0.8% vs 0.7% for
Table 1. Baseline Patient Characteristics (continued)
Characteristic
No. (%)a
No AUD (n = 132 744) AUD (n = 4752)
Psychoses 8068 (6.1) 525 (11.0)
Paralysis 6560 (4.9) 94 (2.0)
Rheumatoid arthritis or collagen vascular disease 6009 (4.5) 93 (2.0)
Metastatic cancer 5858 (4.4) 121 (2.5)
Solid tumor without metastasis 5557 (4.2) 149 (3.1)
Drug abuse 3623 (2.7) 845 (17.8)
Chronic liver disease 3294 (2.5) 970 (20.4)
Lymphoma 2388 (1.8) 31 (0.7)
Chronic blood loss anemia 1073 (0.8) 56 (1.2)
Peptic ulcer disease with bleeding 30 (0.02) 0
AIDS 72 (0.05) 8 (0.2)
Abbreviations: AUD, alcohol use disorder; HCAP,
health care–associated pneumonia; ICF, intermediate
care facility; IQR, interquartile range; SNF, skilled
nursing facility.
a Age in years differs significantly between patients
with and without AUD by the Mann-Whitney
Wilcoxon rank sum test (P < .001). Other variables
also differ significantly (P < .001) between these
groups by Pearson uncorrected χ2 test except for
immunosuppression (P = .009), deficiency anemia
(P = .08), depression (P = .08), chronic blood loss
anemia (P = .005), and peptic ulcer with bleeding
(P = .30).
Table 2. Initial Treatment
Characteristic (Day 0 or 1)
No. (%)
P ValueaNo AUD (n = 132 744) AUD (n = 4752)
Intensive care unit admission 32 321 (24.3) 1852 (39.0) <.001
Vasopressor 8202 (6.2) 539 (11.3) <.001
Invasive mechanical ventilation 9982 (7.5) 780 (16.4) <.001
Antibiotics received, No.
1 29 454 (22.2) 969 (20.4)
<.001
2 57 086 (43.0) 1908 (40.2)
3 28 942 (21.8) 1129 (23.8)
≥4 17 262 (13.0) 746 (15.7)
Piperacillin-tazobactam 29 802 (22.5) 1246 (26.2) <.001
Aminoglycosides 2754 (2.1) 79 (1.7) .049
Anti-MRSA agents 42 212 (31.8) 1563 (32.9) .11
Antipseudomonal carbepenem 4175 (3.1) 134 (2.8) .21
Third-generation cephalosporin 60 004 (45.2) 2217 (46.7) .048
Antipseudomonal cephalosporin 12 465 (9.4) 344 (7.2) <.001
Respiratory quinolone 54 798 (41.3) 1986 (41.8) .48
Antipseudomonal quinolone 50 017 (37.7) 1793 (37.7) .94
Macrolide 53 104 (40.0) 1968 (41.4) .05
Guideline antibiotic
Other antibiotic 20 380 (15.4) 763 (16.1)
.50
Fully HCAP 12 700 (9.6) 464 (9.8)
Partial HCAP 22 303 (16.8) 801 (16.9)
Community-acquired pneumonia 77 361 (58.3) 2724 (57.3)
Abbreviations: AUD, alcohol use disorder; HCAP,
health care–associated pneumonia; MRSA, methicillin-
resistant Staphylococcus aureus.
a P values are based on Pearson uncorrected χ2 test.
JAMANetworkOpen | InfectiousDiseases Alcohol Use Disorders and Outcomes of Community-Acquired Pneumonia
JAMA Network Open. 2019;2(6):e195172. doi:10.1001/jamanetworkopen.2019.5172 (Reprinted) June 7, 2019 6/13
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 07/29/2019
K pneumoniae,0.6%vs 1.2% for P aeruginosa, and 3.3% vs 4.0% for organisms resistant to guideline-
recommended therapy for CAP (eTable 4 in the Supplement). Comparedwith patients without AUD,
those with AUD were slightly more likely to receive broad-spectrum antibiotics, including
piperacillin-tazobactam (26.2% vs 22.5%; P < .001) but equally as likely to receive anti–methicillin-
resistant S aureus agents (32.9% vs 31.8%; P = .11). Two-thirds of patients with AUD who were
receiving broad-spectrum antibiotics did not have other risk factors for resistant organisms.
Outcomes
In unadjusted analysis, compared with patients without an AUD, those with an AUDwere associated
withmore late ICU admissions (13.4% vs 8.1%; P < .001), need for late IMV (13.7% vs 6.1%; P < .001),
late vasopressor use (10.7% vs 5.8%; P < .001), increased median LOS (6 [interquartile range (IQR),
3-10] vs 5 [IQR, 3-8] days; P < .001), and higher median hospitalization cost ($10 425 [IQR, $5705-
$21 282] vs $8309 [IQR, $5056-$14 658]; P < .001). Compared with patients with AUD alone, those
with AUD and AWS experienced more late ICU admission (26.7% vs 10.6%), late IMV (25.4% vs
10.8%), and vasopressor use (17.0% vs 9.1%); increasedmedian LOS (8.0 [IQR, 5.0-14.0] vs 5.0 [IQR,
3.0-9.0] days); and higher median cost ($16 260.7 [IQR, $8164.9-$32 825.6] vs $9374.8 [IQR,
$5289.8-$17 769.7]) (Table 3).
Multivariable Analyses
In models that adjusted for age, sex, race, and health insurance, the presence of an AUDwas
associated with increasedmortality (OR, 1.40; 95% CI, 1.25-1.56), late ICU admission (OR, 1.62; 95%
Figure 1. Cultured Organisms in PatientsWith Community-Acquired Pneumonia (CAP) by Presence
or Absence of Alcohol Use Disorder (AUD)
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Table 3. Observed (Unadjusted) Outcomes by AUD Category
Characteristica No AUD (n = 132 744) AUD Without AWS (n = 3747) AUD With AWS (n = 1005)
In-hospital mortality, No. (%) 9673 (7.3) 289 (7.7) 78 (7.8)
Late (≥day 2) ICU admission, No./total No. (%)b 8134/100 423 (8.1) 254/2391 (10.6) 136/509 (26.7)
Late (≥day 2) IMV, No./total No. (%)c 7463/122 762 (6.1) 343/3185 (10.8) 200/509 (25.4)
Late (≥day 2) vasopressor use, No./total No. (%)d 7233/124 542 (5.8) 303/3335 (9.1) 149/878 (17.0)
Length of stay, median (IQR), d 5.0 (3.0-8.0) 5.0 (3.0-9.0) 8.0 (5.0-14.0)
Cost, median (IQR), $ 8308.7 (5056.4-14 657.5) 9374.8 (5289.8-17 769.7) 16 260.7 (8164.9-32 825.6)
Abbreviations: AUD, alcohol use disorder; AWS, alcohol withdrawal syndrome; ICU,
intensive care unit; IMV, invasive mechanical ventilation; IQR, interquartile range.
a Except for in-hospital mortality (P = .52), all variables differed statistically significantly
among the 3 groups by Pearson uncorrected χ2 or Kruskal-Wallis rank analysis of
variance (length of stay and cost) test.
b Patients with ICU admission on day 0 or 1 were excluded.
c Patients with IMV on day 0 or 1 were excluded.
d Patients with vasopressor use on day 0 or 1 were excluded.
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CI, 1.44-1.82), late IMV (OR, 2.05; 95% CI, 1.85-2.27), late vasopressor use (OR, 1.66; 95% CI,
1.49-1.85), LOS (risk-adjusted geometric mean ratio, 1.24; 95% CI, 1.20-1.27), and cost (risk-adjusted
geometric mean ratio, 1.33; 95% CI, 1.28-1.38). When comorbidities and risk factors for resistance
were added, most associations were attenuated (Figure 2A). Alcohol use disorder was no longer
associated with mortality (OR, 0.89; 95% CI, 0.77-1.02), late ICU admission (OR, 1.01; 95% CI,
0.87-1.16), or vasopressor use (OR, 1.04; 95% CI, 0.91-1.18). Alcohol use disorder did remain
associated with late IMV (OR, 1.28; 95% CI, 1.12-1.46), LOS (risk-adjusted geometric mean ratio, 1.04;
95% CI, 1.01-1.06), and cost (risk-adjusted geometric mean ratio, 1.06; 95% CI, 1.03-1.09).
When patients with AUDwere stratified by the presence of AWS, we did not observe an
association between AUD and outcomes for patients without AWS. Those with AWS had significant
increases in late ICU admission (OR, 2.46; 95% CI, 1.92-3.16), vasopressor use (OR, 1.43; 95% CI,
1.15-1.79), late IMV (OR, 2.55; 95% CI, 2.07-3.16), LOS (risk-adjusted geometric mean ratio, 1.28; 95%
CI, 1.22-1.34), and costs (risk-adjusted geometric mean ratio, 1.35; 95% CI, 1.27-1.43) but lower
adjustedmortality (OR, 0.72; 95% CI, 0.55-0.94) (Figure 2B). Although the association of AUDwith
each outcome was tested in 3 separate models, most P values were less than .01, and Bonferroni-
Holm adjustment of P values for these triplicate analyses did not change the statistical significance
(α = .05) of any test result. However, after this adjustment, the unexpected lower mortality with
AWS is only marginally significant (P = .045) andmay be a statistical false-positive.
Discussion
In this large nationwide sample of patients hospitalized with pneumonia, patients with AUD differed
from thosewithout AUD in several important ways thatmight be expected. Patients with AUDwere
younger, more oftenmale, andmore likely to be insuredwithMedicaid insurance. They also hadmore
comorbidities, especially liver disease, drug abuse, and psychosis; appeared to havemore serious
Figure 2. Associations of Alcohol Use Disorder (AUD)With Outcomes of Hospitalization for Community-Acquired Pneumonia
Outcome
Mortality
Without AWS
With AWS
Late ICU
Less Likely
With AUD
More Likely
With AUD
0.5 2 3.51.5 2.5 3
OR (95% CI)
1
Without AWS
With AWS
No. of
Patients
OR
(95% CI)
137 496
103 323
126 734
128 755
137 496
131 574
Full model: relative to no AUDB
Late IMV
Without AWS
With AWS
Late vasopressor
Without AWS
With AWS
LOS
Without AWS
With AWS
Cost
Without AWS
With AWS
Outcome
Mortality
Reduced model
Full model
Late ICU
Reduced model
Full model
No. of
Patients
137 496
OR
(95% CI)
1.40 (1.25-1.56)
0.89 (0.77-1.02)
1.62 (1.44-1.82)
1.01 (0.87-1.16)
2.05 (1.85-2.27)
1.28 (1.12-1.46)
1.66 (1.49-1.85)
1.04 (0.91-1.18)
1.24 (1.20-1.27)
1.04 (1.01-1.06)
1.33 (1.28-1.38)
1.06 (1.03-1.09)
0.94 (0.81-1.09)
0.72 (0.55-0.94)
0.79 (0.67-0.93)
2.46 (1.92-3.16)
1.06 (0.92-1.23)
2.55 (2.07-3.16)
0.95 (0.82-1.10)
1.43 (1.15-1.79)
0.98 (0.96-1.01)
1.28 (1.22-1.34)
0.99 (0.96-1.02)
1.35 (1.27-1.43)
103 323
126 734
128 755
137 496
131 574
Any AUD vs no AUDA
Late IMV
Reduced model
Full model
Late vasopressor
Reduced model
Full model
LOS
Reduced model
Full model
Cost
Reduced model
Full model
Less Likely
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More Likely
With AUD
0.5 2 3.51.5 2.5 3
OR (95% CI)
1
A, Overall association of AUDwith outcomes of hospitalization for community-acquired
pneumonia. B, Association of AUD with outcomes of hospitalization for community-
acquired pneumonia stratified by presence of alcohol withdrawal syndrome (AWS). Late
intensive care unit (ICU) admission, late invasive mechanical ventilation (IMV), and late
vasopressor use were defined as arising on day 2 or later and were studied only among
patients for whom the respective late outcome was not present earlier. Costs were
studied conditionally only among patients with positive costs and from hospitals with
greater than 50% of all patients also with positive costs. Patients with no cost were
excluded. Reducedmodels were adjusted for age, sex, race, and insurance status. Full
models were adjusted for the preceding variables as well as the presence of
comorbidities and components of the health care–associated pneumonia definition. LOS
indicates length of stay; OR, odds ratio.
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pneumonias as measured by admission to the ICU, use of IMV, or use of vasopressors; and
experienced longer LOS and higher costs. Age-adjusted differences in mortality appear to have been
attributable to alcohol-related comorbidities because theywere no longer present after adjustment
for comorbidities. Even then, AUD remained associated with poorer clinical outcomes and higher use
of health care resources, including the need for mechanical ventilation after admission, longer LOS,
and higher costs. These associations appear to be attributable to AWS because theywere not present
among the subgroup of patients without AWS.We found no evidence that unmeasured factors, such
as homelessness, poverty, or direct toxic effects of alcohol on the immune system, contributed to
outcomes for patients with AUD. In addition, we found that, despite theoretical reasons to expect
gram-negative organisms to predominate, the organismmost commonly cultured from patients with
AUDwas S pneumoniae. Patients with AUDwere actually slightly less likely than others to harbor
resistant organisms, such as P aeruginosa. Nevertheless, patients with AUDwere slightly more likely
to receive broad-spectrum antibiotics, primarily because they had a more severe clinical
presentation.
The last large study of pneumonia and AUD in the United States was conductedmore than 25
years ago. Saitz et al4 examined 23 198 patients admitted to Massachusetts hospitals with a principal
diagnosis of pneumonia; similar to our study, they found that 824 patients (3.6%) had an AUD. They
also found that, after adjustment for demographics and comorbidities, patients with AUDweremore
likely to be admitted to the ICU and had higher costs and longer LOS, butmortality was similar to that
of patients without AUD. They concluded that alcoholism alone was a factor associated with
pneumonia, probably owing to the direct toxic effects of alcohol on the respiratory and immune
systems. Although it is true that alcohol decreases mucociliary clearance, impairs alveolar19 and cell-
mediated immunity, and decreases the function of alveolar macrophages and neutrophils,20-23 we
found that, after removing patients with AWS—something Saitz et al4 did not do—there was no
residual deleterious association of AUDwith patient outcomes. Despite the theoretical association of
alcohol’s direct toxic effect, AUD by itself was not associated with pneumonia outcomes.
Similarly, there are several reasons to believe that patients with AUDwould have infections with
gram-negative organisms resistant to recommended empirical therapy for CAP. Alcohol alters the
oropharyngeal flora, inviting colonization by gram-negative organisms. It also blunts the cough and
gag reflexes,24 predisposing patients to aspiration.25 For these reasons, guidelines from the
Infectious Diseases Society of America26 identify alcoholism as a risk factor for gram-negative
infections, including Klebsiella and Pseudomonas. However, only 2 small studies support this
association: 1 study of 25 patients in the ICU on an island in the Indian Ocean27 and a study of 50
patients, 16 of whom had an AUD, in an emergency department in Barcelona, Spain.28 A third study
found that alcoholism is associated with Klebsiella in South Africa and Taiwan but not in the rest of
the world.29 In contrast, several much larger prospective and retrospective studies have found that
alcoholism is primarily associatedwith S pneumoniae infection.2,4,30 Our study supports these latter
works by presenting more cases than all the other studies combined in a contemporary, multi-
institutional sample that is broadly representative of US hospitals. More important, we examined the
resistance patterns of the organisms isolated and found that patients with AUDwere notmore likely
to harbor organisms resistant to standard CAP therapy. Given these findings, it may be appropriate to
remove alcohol as a risk factor for multidrug-resistant organisms in the next iteration of the
guidelines.
We believe the results of this study are important becausewe found thatmore than one-quarter
of patients with pneumoniawho had an AUD received an antipseudomonal penicillin, andmore than
one-third received anti–methicillin-resistant S aureus agents. In most of these patients, AUD was
their only risk factor. In addition, the association of S pneumoniaewith AUD strongly supports the
necessity to promote pneumococcal vaccination of these patients.31,32
On admission to the hospital, abstinence from alcohol can lead to AWS. Monte et al33 assessed
factors determining the survival of hospitalized patients with AWS. Cirrhosis, delirium tremens,
hallucinations, and seizures increase the risk for adverse outcomes in patients with AWS.33-35
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Development of delirium tremens is commonly associated with AWS and is a major contributor to
AWS-related deaths.36,37 To our knowledge, our study is the first to evaluate the contribution of AWS
to outcomes in pneumonia and shows that patients with AWS have increased late transfers to the
ICU, need for IMV, and need for vasopressors as well as increased LOS and cost. Promptmanagement
of these patients based onwithdrawal severity38might help reduce the use of health care resources.
Paradoxically, the patients with AWS had lower adjusted mortality than patients without AUD. The
reasons for this finding are unclear. It is possible that reasons for ICU admission and IMV use among
patients with AWS differ from those of other patients with pneumonia and therefore do not carry the
same prognostic value. The fact that unadjustedmortality for patients with AWSwas slightly higher
than that for other patients with AUD supports this hypothesis. Alternatively, it may represent a
chance finding.
Limitations
Our study has several limitations. By relying on ICD-9-CM codes, wemay have failed to identify some
patients with AUD. However, suchmisclassification seems unlikely to have substantially distorted
the effects we observed. Also, we could neither quantify alcohol use nor, with these primarily
administrative data, adjust for physiological measures, such as vital signs. This limitation could have
resulted in misclassification of pneumonia severity, although we did assess for indirect measures of
severity, such as IMV and vasopressor use, and the variables we obtained have excellent prognostic
ability for inpatient death.39We controlled for an extensive list of potential confounders by including
them as covariates in mixed logistic regression analyses. An alternative strategy for control of
confounding would have been to compare patients with AUDwith individually matched sets of
patients without AUD treated in the same hospital. We preferred to rely on amore classic modeling
approach because our stagewise adjustments would have required different matched sets at each
stage; also, close, within-hospital matching using 46 covariates at the final stage would have
sacrificed considerable precision by omitting a large fraction of patients without AUD. The use of
mixedmodels, with hospital as the random effects, also accounts for interhospital variability in a
manner that supports generalization of results beyond the institutions that contribute information to
the Premier Healthcare Database. Our etiologic findings are based on relative frequencies of cultured
organisms in culture-positive samples and implicitly assume that these organisms also characterize
the unobserved distributions in patients with false-negative samples and among those from whom
cultures were not obtained.
Conclusions
In this study, patients with AUD composed 1 in 30 patients hospitalized with pneumonia and had
age-adjusted outcomes that were poorer than those of other patients. The reason for this finding
appears to be excess comorbidities, such as chronic liver disease, smoking, andmalnutrition, among
patients with AUD. In addition, patients with AWSwere at elevated risk of clinical deterioration and
experienced longer LOS and substantially higher cost. Despite theoretical concerns about the effects
of alcohol on local flora and defensemechanisms, organisms cultured frompatients with pneumonia
who had an AUD in this study were not more likely to be resistant to antibiotics for CAP. Treatment
should therefore include routine CAP therapy and close monitoring for AWS.
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